Naslov
Angiotensin receptor-neprilysin inhibition in acute myocardial infarction
(Angiotensin receptor–neprilysin inhibition in acute myocardial infarction)

Autori
Pfeffer, Marc A. ; Claggett, Brian ; Lewis, Eldrin F. ; Granger, Christopher B. ; Køber, Lars ; Maggioni, Aldo P. ; Mann, Douglas L. ; McMurray, John J.V. ; Rouleau, Jean-Lucien ; Solomon, Scott D. ; Steg, Philippe G. ; Berwanger, Otavio ; Čikeš, Maja ; De Pasquale, Carmine G. ; East, Cara ; Fernandez, Alberto ; Jering, Karola ; Landmesser, Ulf ; Mehran, Roxana ; Merkely, Béla ; Vaghaiwalla Mody, Freny ; Petrie, Mark C. ; Petrov, Ivo ; Schou, Morten ; Senni, Michele ; Sim, David ; van der Meer, Peter ; Lefkowitz, Martin ; Zhou, Yinong ; Gong, Jianjian ; Braunwald, Eugene

Kolaboracija
PARADISE-MI Investigators and Committees

Izvornik
The New England journal of medicine (0028-4793) 385 (2021), 20; 1845-1855

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
heart failure

Sažetak
Sacubitril-Valsartan in Acute Myocardial Infarction In a randomized trial, 5661 patients with acute myocardial infarction and a reduced left ventricular ejection fraction, pulmonary congestion, or both were assigned to receive either sacubitril-valsartan or ramipril. At a median of 22 months, there was no significant difference between the two groups in the incidence of death from cardiovascular causes or incident heart failure. Background In patients with symptomatic heart failure, sacubitril-valsartan has been found to reduce the risk of hospitalization and death from cardiovascular causes more effectively than an angiotensin-converting-enzyme inhibitor. Trials comparing the effects of these drugs in patients with acute myocardial infarction have been lacking. Methods We randomly assigned patients with myocardial infarction complicated by a reduced left ventricular ejection fraction, pulmonary congestion, or both to receive either sacubitril-valsartan (97 mg of sacubitril and 103 mg of valsartan twice daily) or ramipril (5 mg twice daily) in addition to recommended therapy. The primary outcome was death from cardiovascular causes or incident heart failure (outpatient symptomatic heart failure or heart failure leading to hospitalization), whichever occurred first. Results A total of 5661 patients underwent randomization ; 2830 were assigned to receive sacubitril-valsartan and 2831 to receive ramipril. Over a median of 22 months, a primary-outcome event occurred in 338 patients (11.9%) in the sacubitril-valsartan group and in 373 patients (13.2%) in the ramipril group (hazard ratio, 0.90 ; 95% confidence interval [CI], 0.78 to 1.04 ; P=0.17). Death from cardiovascular causes or hospitalization for heart failure occurred in 308 patients (10.9%) in the sacubitril-valsartan group and in 335 patients (11.8%) in the ramipril group (hazard ratio, 0.91 ; 95% CI, 0.78 to 1.07) ; death from cardiovascular causes in 168 (5.9%) and 191 (6.7%), respectively (hazard ratio, 0.87 ; 95% CI, 0.71 to 1.08) ; and death from any cause in 213 (7.5%) and 242 (8.5%), respectively (hazard ratio, 0.88 ; 95% CI, 0.73 to 1.05). Treatment was discontinued because of an adverse event in 357 patients (12.6%) in the sacubitril-valsartan group and 379 patients (13.4%) in the ramipril group. Conclusions Sacubitril- valsartan was not associated with a significantly lower incidence of death from cardiovascular causes or incident heart failure than ramipril among patients with acute myocardial infarction. (Funded by Novartis ; PARADISE-MI ClinicalTrials.gov number, NCT02924727.)

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA